HIV in Prison Situation in Frankfurt am Main

Similar documents
Models of good practice in drug treatment in Europe. Project group

Drug Policy and the HIV Movement. SAULIUS CAPLINSKAS MD, PhD

INTRAVENOUS INJECTING DRUG USE.

Drug treatment and prevention in Tartu prison. Maret Miljan Department of Prisons Ministry of Justice Estonia

GLOBAL DRUG POLICY AND THE HIV/IDU EPIDEMIC IN EASTERN EUROPE AND CENTRAL ASIA. The critical need to scale up opioid substitution therapy

HIV and Hepatitis C Infection among Persons who Inject Drugs: Global Overview and Policy Implications

Technical Guidance Note for Global Fund HIV Proposals

Dr. dr. Diah Setia Utami, SpKJ, MARS Deputy of Rehabilitation Narcotic National Board of Republic of Indonesia

DUBLIN DECLARATION ON HIV/AIDS IN PRISONS IN EUROPE AND CENTRAL ASIA

CitiWide Harm Reduction

Opioid Withdrawal, Opioid Substitution, and HIV Infection

As a result of this training, participants will be able to:

Note: Staff who work in case management programs should attend the AIDS Institute training, "Addressing Prevention in HIV Case Management.

Viral Hepatitis. WHO Regional Office for Europe July 2013

The new German strategy on HIV, Hepatitis B, C and STI, an integrated approach. Ines Perea Ministry of Health, Germany

The Comprehensive Package: The simple truth about our response to drug related HIV. Dr. Monica Beg, Signe Rotberga UNODC

As a result of this training, participants will be able to:

KAZAKHSTAN. National Focal Point. Drug Abuse and Drug Dependence Treatment Situation. Territory : 2,717,300 km 2 Capital: Astana BASIC DATA

Opioid Withdrawal, Opioid Substitution, and HIV Infection

ANNUAL PROJECT PROGRESS REPORT FOR 2008 (draft)

Poland nationalupdate

Strategies of drug users to avoid infection with hepatitis C

Medical Director. and in prison settings in Romania. Ministry of Justice National Administration of Penitentiaries L IŢ

ECDC s role in the fight against HIV/AIDS in Europe

Harm Reduction in Nigeria

Mid-term Review of the UNGASS Declaration of. Commitment on HIV/AIDS. Ireland 2006

Minutes of the 18 th HIV/AIDS Think Tank Meeting 5 and 6 June 2012, Luxembourg

Opioid Withdrawal, Opioid Substitution Treatment, and HIV Infection

Harm reduction among drug users in Spain

OST saves lives it s official! OST a key to HIV prevention Opioid Substitution Treatment in Germany A Story of Success

TB: INTEGRATION IN HARM REDUCTION PACKAGES. ICF "AIDS Foundation East-West (AFEW Ukraine) Tbilisi, 2015

26 28 May 2010, Almaty, Kazkhstan. Nina Kerimi UNODC Regional Project Coordinator 1

The impact of economic recession on drug users and drug treatment

Prevention and control of Hepatitis B and C among vulnerable groups Estonia: People who use drugs

Drug Use, Prisons and Compulsory Drug Treatment Centers

Civil Society Driven Response in Ukraine: A program making a difference and bringing results

HIV/AIDS Prevention, Treatment and Care among Injecting Drug Users and in Prisons

Strategies to Reduce Harm and HIV/AIDS Infection among Drug Using Populations

HIV in Russia. Cost-effectiveness of Treating Injection Drug Users with Antiretroviral Therapy

This document was generated by the Reference Group to the United Nations on HIV and Injecting Drug Use.

HIV AND PEOPLE WHO INJECT DRUGS

COUNTRY TABLE. MONTENEGRO.

Version for the Silent Procedure 29 April Agenda item January Hepatitis

U.S. Counties Vulnerability to Rapid Dissemination of HIV/HCV Infections Among People Who Inject Drugs

ECDC and Spanish Ministry of Health workshop:

HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS

Additional North Carolina Projects

Hepatitis prevention in the context of HIV prevention point work in Latvia

The National Infrastructure for Hepatitis C: Is There Anyone Home? December 21, 2015

Presenters. Session Objectives. Session Overview. Cluster Investigations in Rural Wisconsin

Pilot Condom Distribution in Czech Prison

Guidelines For Services Providing Injecting Equipment

Infectious Disease and the Opioid Epidemic: Correctional Health

HIV epidemic around the Baltic Sea

Prevention services for minors in prisons

Just Out of Reach: Women Who Use Drugs, Stigma and Barriers to Care Erin Bortel and Lyla Hunt AIDS Institute Office of Drug User Health

Thirty years of harm reduction in the Netherlands HCV elimination ahead?

A national multidisciplinary healthcare network for treatment of hepatitis C in PWID in Slovenia Prof. Mojca Matičič, MD, PhD

The role of UNODC in working law enforcement agencies to promote harm reduction. IHRC, Bangkok, 23 April 2009

Treatment and Harm Reduction in Prisons. Republic of Moldova

Goal of this chapter. 6.1 Introduction Good practices for linkage to care General care for people living with HIV 84

COUNTRY REPORT: EPIDEMIOLOGICAL SITUATIONS AND PROJECT ACTIVITIES

Alcohol policymaking in the context of a larger Europe

Drug Use, Harm Reduction, and HIP

EMCDDA-update HIV/HCV among people who inject drugs: situation and response

Public drug policies Catalonia

Knowledge, Attitudes and Behavior Related to HIV/AIDS among Transport Sector Workers

HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS

Prof. Dr Heino Stöver Faculty of Health and Social Work University of Applied Sciences Frankfurt, Germany

UNGASS Declaration of Commitment on HIV/AIDS: Core Indicators revision

What s The Point? The unique role of pharmacists in HIV/HCV. prevention efforts BAY AREA AND NORTH COAST AREA APRIL 30, 2016

Hepatitis C : Screening and Prevention Strategies

THE GAP REPORT 2014 PRisOnERs

Legal and institutional framework of combating drugs abuse in the. Republic of Croatia

QuADS Organisational Standards and Professional Competencies in needle exchange

Drug demand reduction and harm reduction: complementary approaches. Gilberto Gerra Chief Global Challenges Section Division for Operations

mhtml:file://c:\2014\articoli\x_journal FOR DRUG ADDICTION AND ALCOH...

NIDA Responds to the Syndemic of Opioids, Viral Hepatitis and HIV. Wilson M. Compton, M.D., M.P.E. Deputy Director, National Institute on Drug Abuse

Feedback from joint country mission on HIV and hepatitis B and C of ECDC and EMCDDA experts to Latvia, September 2014

Statement by the Portuguese Deputy Minister for Health. Vienna, 8 March 2010

Improving Access to Test and Counselling Services for Injection Drug Users: Most Recent Experience from Portugal. Henrique Barros

UNAIDS 99.1E (English original, March 1999) This document, presenting a speech given at the United Nations General Assembly Special Session on Drugs,

Continued in Part II (additional reading list at end of Part II)

Prevention of and Immunisation against Hepatitis B and C

Should buprenorphine be covered for maintenance treatment in opioid dependent persons?

Compulsory detention as drug treatment and the impact on HIV outcomes

Methadone Treatment as a Harm Reduction Strategy, Gender Sensitive Programming and Evidence-based Strategies

NDPHS Expert Group on HIV/AIDS and Associated Infections Progress report 27 October, Chair Dr. Ali Arsalo and ITA Ms Outi Karvonen

HARM REDUCTION & THE OPIOID EPIDEMIC. CHELSEA RAINWATER Co-Founder & Executive Director No Overdose Baton Rouge

epidemic among vulnerable groups

Horizontal Working Party on Drugs EMCDDA contribution towards a methodological framework for monitoring drugs and prison in Europe

Implementing TB/HIV collaborative activities in prison settings: where are we?

Background. Population/Intervention(s)/ Comparison/Outcome(s) (PICO)

Place of addiction-informed comprehensive treatment in HIV care

The evolution of the HIV/AIDS outbreak among IDUs in Romania

Monitoring harm reduction implementation in European prisons: public health and human rights approaches

Contents. I. Policy and principles

What is injection drug use?

HIV Risk Behaviour in Irish Intravenous Drug Users

Targeted Outreach & Other Strategies for Increasing HCV Testing

Transcription:

HIV in Prison Situation in Frankfurt am Main European Project ROME-SEMINAR, May 14.-15., 2008 Horst Herkommer, Sella Oneko Praxis Psychosoziale Beratung Frankfurt am Main Germany

General remark: Situation in Germany Situation in prisons: 76,500 prisoners are in Germany. 17,000 of all prisoners are iv. Drug users, there are 22%. But only about 500 up to 800 of them receive methadon treatment during detention (<3%), 10 times less than in freedom, where about 30% receive methadone treatment. Wasted opportunities mainly to reduce the iv. Drug use while in detention, and thus reduce the risk of infection (HBV, HCV, HIV). Reduction of mortality due to dismissal of drug relapse and overdose. The prevalence of HIV-positive prisoners, according to recent study between 0.8% and 1.2%. Sources: Schulte et al, 2008 / Stallwitz / Stöver 2007 / Farrell 2005; Singleton et al. 2005 / Radun 2007 / Schulte 2008

HIV phenomenon in the women s prison (Frankfurt III) Nationality of Inmates in Frankfurt III (Women's Prison) Total No.: 296 Persons Approx. 54% between 21-30 years of age Approx. 94% of the women were formerly unemployed 53% Foreign German 47% 25% did not specify source of income (criminal activities and prostitution assumed) Source: Holler, Frankfurt women s prison (III)

HIV phenomenon in the women s prison (Frankfurt III) 140 120 100 80 60 40 20 0 History of intravenous Drug use (IDU) IDU Non-IDU 9 8 7 6 5 4 3 2 1 0 Intravenous Drug Use (IDU) and HIV in Prison 8 5 3 1 Foreign German German Foreign IDU Non - IDU Source: Holler, Frankfurt women s prison (III)

HIV phenomenon in the women s prison (Frankfurt III) ART in Prison (With ART = 1 Person ART Naive; 2 Persons with a high CD4 Count without ART) 7 10 12 10 10 8 7 6 4 2 HIV-Infected HIV/HCV Coinfection 0 Without ART With ART (17 HIV-infected Persons; 6 not tested) Source: Holler, Frankfurt women s prison (III)

Prisons and external drug-counselling in Hesse External Drug Counselling in all Prisons in Hesse The External Drug Counselling Services has been operating in prisons in Hesse since the 1970s offering following services: Placement of persons to inpatient treatment in an open prison Placement of persons to part time inpatient instituitions, outpatient treatment and selfhelp insitutions Accommodation in therapeutic institutions (Therapy instead of punishment) Counselling and motivation work especially during substitution treatment and encouragement therapy willingness Prevention work with inmates who are at risk of drug abuse Continuing treatment drug addicted persons during prison leave or after release

Light and Shadows: strengths and weaknesses in the system Light: All prisoners with HIV-infection have the opportunity to receive treatment (HAART). Shadows: Capacities: Drug counselling takes place every 2 weeks due to staffing deficits Break off of therapy Lack of Collaboration Wide ranging of counselling services

Substitution treatment Country Detoxication Long term treatment Inmates with short sentences Inmates with long sentences Relapse prophylaxis Substitution No. of inmates in Methadoneprogrammes Austria Methadone 345 (11/2000) Germany Methadone ca. 500-800 In some prisons In all prisons In most prisons In no prison * Psychosocial counselling accompanies all substitution programmes in Hesse A practical guide for substitution treatment in prison conditions should doctors encourage the substitution treatment in prisons should be extended. (Kastelic/Pont Stöver 2008; http://www.archido.de/index.php?lang=en).

Adressing the needs of HIV-infected persons Medical needs administered by infectious disease specialist in prison Drug and psychosocial counselling for HIV infected Prisoners Individual therapy approach Continuity of counselling after prison Therapy-groups for HIV-infected persons Possibility of transferral if medical needs do not allow for stay in prison Extra dietary needs addressed if necessary

Problems pending and possible solutions 40% of the inmates have debts when they leave prison This leads to existential and financial problems after prison sentence there are few support measures to aid these people 42% of all inmates have at least one child. There are as yet not enough support measures for the parents and children With the current staffing, these problems are not solved. Used: More money, more staff.

Suggestions to be brought to the attention of the European Commission Systematic Hepatitis vaccination Programme for inmates and employees Training / peer-group programmes about HIV/AIDS, Hepatitis or IDU for inmates and employees Increased offer for HIV and Hepatitis testing and counselling and advice Low threshold and free access to preventionutensils (sterile syringes and equipment, condoms, lubricants) Extension of the methadon treatment in prison. Adherence to binding regulations outside prison. Increased cooperation with external medical service

Suggestions on further work as a follow-up of this experience Basically: Formulating an EU definition of drugaddiction as a chronic illness according to WHO as an authentic standard for all EU-Members! We need an instrument for observation, how far the WHO definition is met. Database to establish the status quo and the changes in the conditions of HIV-therapy and substitution for prisoners in Europe. This means a network for data collection. Goal: In and out the Equivalence of care.

STATEMENT OF FUNDAMENTAL PRINCIPLES* Principle 1: People in prison are part of our communities. Principle 2: People in prison have a right to health. Principle 3: Good prison health is good public health. Principle 4: Protecting the health of prisoners, and reducing the transmission of disease in prisons, also protects the health of prison staff. Principle 5: Sex and injecting drug use occur in prison, and are widespread in many prisons. Principle 6: Harm reduction, rather than zero-tolerance, must be the pragmatic policy basis for fighting HIV/AIDS in prisons and in providing HIV/AIDS care. Principle 7: HIV/AIDS in prisons is a major problem in many countries, and States must act collectively and cooperatively in the fight against the epidemic. Principle 8: Action to fight Hepatitis C in prisons is as crucial as is action to fight HIV/AIDS, and must be integrated into all initiatives addressing HIV/AIDS prevention and treatment.

Prison Health is Public Health * * DUBLIN DECLARATION ON HIV/AIDS IN PRISONS IN EUROPE AND CENTRAL ASIA, 2004

WHO defines drug addiction as a chronic or recurrent condition, characterized by the compulsive use of toxic substances which affect the central nervous system o the user and result in a state of physical and / or psychological dependence on these substances. Drug addiction is harmful to the individual and / or society (ICD 10)